#USA #New York #Class Action #Bronstein Gewirtz #Pacira BioSciences

Pacira BioSciences Investors Encouraged to Join Class Action Lawsuit

A recent announcement from Bronstein, Gewirtz & Grossman LLC has brought to light a class action lawsuit against Pacira BioSciences, Inc., a well-known player in the biopharmaceutical industry. Investors who have sustained substantial financial losses are being urged to participate in this legal action aimed at recovering damages.

Class Action Details

The class action lawsuit has been initiated on behalf of all individuals and entities that acquired Pacira securities that were purchased between August 2, 2023, and August 8, 2024. Within this timeframe, investors are encouraged to join the case by visiting the law firm's dedicated site at bgandg.com/PCRX.

Allegations Against Pacira

The lawsuit raises critical allegations against the company and its officers. It claims that throughout the specified class period, Pacira made numerous false and misleading statements regarding its business operations, financial performance, and the efficacy of its prominent product, Exparel. Notably, the complaint alleges:
1. Pacira overstated the efficacy of Exparel, claiming it could provide pain relief for up to 72 hours when it is only approved for a duration of 24 hours.
2. Marketing strategies touted the safety of Exparel for specific surgical procedures, despite lacking adequate approval and instructions.
3. A significant portion of Pacira's revenue stemmed from off-label marketing, which raises red flags regarding the company's practices and transparency.
4. As a result of these actions, the company’s financial statements have been characterized as materially false and misleading throughout the relevant period.

Next Steps for Investors

A class action has already been established to pursue the claims against Pacira. For those affected by the alleged misconduct, the opportunity to join as a lead plaintiff exists, with a deadline set for March 14, 2025. However, participating as a lead plaintiff is not a requirement to benefit from any potential recovery resulting from this lawsuit.

Investors can easily access the complaint to review its contents by visiting the firm’s website or can reach out to attorneys Peretz Bronstein or Nathan Miller via the contact number provided. Notably, Bronstein, Gewirtz & Grossman, LLC, operates on a contingency fee basis. This means that their fees are contingent upon successfully securing a recovery, which would entail the court covering costs based on a percentage of what is recovered.

Why Choose Bronstein, Gewirtz & Grossman

Recognized nationally, Bronstein, Gewirtz & Grossman, LLC specializes in representing investors in securities fraud class actions. Historically, they have successfully recovered hundreds of millions of dollars on behalf of aggrieved investors across the nation. Their track record and focus on investor rights make them a trustworthy ally for those affected by securities violations.

Investors are advised to stay informed about legal updates and can follow the firm on popular social media platforms for more information. As the case develops, it could shape the regulatory landscape for biopharmaceutical companies and their marketing practices.

For further information or inquiries, potential plaintiffs are encouraged to connect with the firm's dedicated representatives to explore their legal options and engage in this significant class action focused on accountability and recovery.